Rheumatology (Oxford, England)
Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry.
Juan Molina-Collada, Lucía Otero-Varela, Paloma Vela, Sara Manrique, Celia Erausquin, Cristina Campos, Javier Manero, Jerusalem Calvo, Lorena Expósito, Javier García González, María Dolores Ruiz Montesinos, Elena Rabadán, Antonio Mera Varela, Inmaculada Ros Vilamajo, María Colazo Burlato
Published: 202510.1093/rheumatology/keaf556
Abstract
OBJECTIVES: To assess the risk of cancer in patients with rheumatoid arthritis (RA) treated with biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). METHODS: We analyzed RA patients from the BIOBADASER III registry, a…
Preview only. Read the full abstract at the source